The estimated Net Worth of Ulrik B. Nielsen is at least $2.43 Million dollars as of 24 January 2022. Ulrik Nielsen owns over 14,287 units of Merrimack Pharmaceuticals Inc stock worth over $559,326 and over the last 12 years he sold MACK stock worth over $552,750. In addition, he makes $1,317,610 as Independent Director at Merrimack Pharmaceuticals Inc.
Ulrik has made over 17 trades of the Merrimack Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 14,287 units of MACK stock worth $60,577 on 24 January 2022.
The largest trade he's ever made was exercising 105,000 units of Merrimack Pharmaceuticals Inc stock on 27 May 2014 worth over $133,350. On average, Ulrik trades about 18,553 units every 120 days since 2012. As of 24 January 2022 he still owns at least 36,968 units of Merrimack Pharmaceuticals Inc stock.
You can see the complete history of Ulrik Nielsen stock trades at the bottom of the page.
Dr. Ulrik B. Nielsen Ph.D. serves as Independent Director of the Company. He has served as a member of our board of directors since January 2015 and is one of our co-founders. Dr. Nielsen led our research and drug discovery in various roles from when he joined us in 2002 to January 2015, including as our Senior Vice President and Chief Scientific Officer from March 2009 until January 2015. Dr. Nielsen has been President and Chief Executive Officer of Tidal Therapeutics, Inc., a biotechnology company, since August 2018. Dr. Nielsen previously served in various capacities at Torque Therapeutics Inc., a biotechnology company, including as President from January 2015 to June 2018, Founder Chairman from November 2017 to June 2018 and Chief Executive Officer from January 2015 to November 2017. Dr. Nielsen also served as Chief Executive Officer of Silver Creek Pharmaceuticals, Inc., a former majority owned subsidiary of ours, from July 2010 to March 2014. Dr. Nielsen also currently serves on the board of directors of Alloy Therapeutics LLC. Dr. Nielsen holds a Ph.D. in molecular biology and an M.S. in biochemistry from the University of Copenhagen.
As the Independent Director of Merrimack Pharmaceuticals Inc, the total compensation of Ulrik Nielsen at Merrimack Pharmaceuticals Inc is $1,317,610. There are no executives at Merrimack Pharmaceuticals Inc getting paid more.
Ulrik Nielsen is 48, he's been the Independent Director of Merrimack Pharmaceuticals Inc since 2018. There are 9 older and 2 younger executives at Merrimack Pharmaceuticals Inc. The oldest executive at Merrimack Pharmaceuticals Inc is Dr. Anthony J. Sinskey Ph.D., Sc.D., 81, who is the Co-Founder and Scientific Advisor.
Ulrik's mailing address filed with the SEC is C/O MERRIMACK PHARMACEUTICALS, INC., ONE BROADWAY 14TH FLOOR, CAMBRIDGE, MA, 02142.
Over the last 13 years, insiders at Merrimack Pharmaceuticals Inc have traded over $1,152,598 worth of Merrimack Pharmaceuticals Inc stock and bought 3,978,994 units worth $28,464,218 . The most active insiders traders include Eric Western Standard Llcwe..., Robert J. Mulroy, and Gary L Crocker. On average, Merrimack Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $459,997. The most recent stock trade was executed by Eric Western Standard Llcwe... on 26 December 2023, trading 49,550 units of MACK stock currently worth $651,583.
merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. through systems biology, which brings together the fields of biology, computing and engineering, merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. such an approach has the potential to make individualized treatment of patients a reality. merrimack's first commercial product, onivydetm (irinotecan liposome injection), was approved by the u.s. fda on october 22, 2015. with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, merrimack is building one of the most robust oncology pipelines in the industry. for more information, please visit merrimack's website at www.merrimack.com or connect on twitter at @merrimackpharma.
Merrimack Pharmaceuticals Inc executives and other stock owners filed with the SEC include: